Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment

International Journal of Oncology

Volumn 38, Issue 6, 2011, Pages 1695-1702

  Yang, Shi Yu ^a   Miah, Anur ^a   Sales, Kevin M ^a   Fuller, Barry ^a   Seifalian, Alexander M ^a   Winslet, Marc ^a,b,c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Chemoresistance; Colorectal cancer; Fluorouracil; p38 mitogen activated protein kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; ENZYME ACTIVATION; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 79955856911     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.982     Document Type: Article

References (28)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
2. Jemal A, Siegel R, Ward E, Murray T, Xu JQ and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
3. American Cancer Society: Cancer facts and figures 2008. Am Cancer Soc, Atlanta, 2008.
4. Jones DV Jr, Winn RJ, Brown BW, Levy LB, Pugh RP, Wade JL 3rd, Gross HM, Pendergrass KB, Levin B and Abbruzzese JL: Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. Cancer 76: 1709-1714, 1995.
5. Szoke D, Gyorffy A, Surowiak P, Tulassay Z, Dietel M and Gyorffy B: Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer. Onkologie 30: 421-426, 2007. (Pubitemid 350194938)
6. Pinedo HM and Peters GF: Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
7. Mader RM, Muller M and Steger GG: Resistance to 5-fluoro-uracil. Gen Pharmacol 31: 661-666, 1998.
8. Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, Wada J, Koga K, Mibu R, Nakamura M and Katano M: Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res 29: 261-270, 2009.
9. Kuno Y, Kondo K, Iwata H, Senga T, Akiyama S, Ito K, Takagi H and Hamaguchi M: Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues. Jpn J Cancer Res 89: 903-909, 1998. (Pubitemid 28486815)
10. Yang SY, Bolvin C, Sales KM, Fuller B, Seifalian AM and Winslet MC: IGF-I activates caspases 3/7, 8 and 9 but does not induce cell death in colorectal cancer cells. BMC Cancer 9: 158, 2009.
11. R Remacle-Bonnet M, Garrouste F, Baillat G, Andre F, Marvaldi J and Pommier G: Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am J Pathol 167: 761-773, 2005. (Pubitemid 41216360)
12. Yang SY, Sales KM, Fuller BJ, Seifalian AM and Winslet MC: Inducing apoptosis of human colon cancer cells by an IGF-I D domain analogue peptide. Mol Cancer 7: 17, 2008.
13. Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A and Morel F: Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur J Cancer 45: 2219-2227, 2009.
14. Lee JT Jr, Steelman LS and McCubrey JA: Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. Int J Oncol 26: 1637-1644, 2005.
15. Okano J and Rustgi AK: Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 276: 19555-19564, 2001.
16. Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-327, 2005. (Pubitemid 40590269)
17. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003. (Pubitemid 36799316)
18. Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P, Avruch J and Rapp UR: Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13- acetate requires Raf and is necessary for transformation. J Biol Chem 269: 7030-7035, 1994.
19. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001. (Pubitemid 32225829)
20. Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, Sun K, Xiong H, Jiang G, Zhang B, Wu M and Wei L: Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8: 375, 2008.
21. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L and Bonavida B: Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 64: 7117-7126, 2004.
22. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R and Lin MF: ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 107: 478-485, 2003. (Pubitemid 37266470)
23. Zhao Y, Shen S, Guo J, Chen H, Greenblatt DY, Kleeff J, Liao Q, Chen G, Friess H and Leung PS: Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res 136: 325-335, 2006. (Pubitemid 44737848)
24. Kim M, Yan Y, Kortum RL, Stoeger SM, Sgagias MK, Lee K, Lewis RE and Cowan KH: Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity. Cancer Res 65: 3986-3992, 2005. (Pubitemid 40775633)
25. Wang X, Martindale JL and Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 39435-39443, 2000. (Pubitemid 32058968)
26. Durai R, Yang SY, Sales KM, Seifalian AM, Goldspink G and Winslet MC: Insulin-like growth factor binding protein-4 gene therapy increases apoptosis by altering Bcl-2 and Bax proteins and decreases angiogenesis in colorectal cancer. Int J Oncol 30: 883-888, 2007.
27. Zamzami N, Brenner C, Marzo I, Susin SA and Kroemer G: Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16: 2265-2282, 1998. (Pubitemid 28220657)
28. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R and de Gramont A: Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27: 872-877, 2009.